Preloader

Myelodysplastic Syndrome (MDS) Panel

Myelodysplastic Syndromes (MDS) are a group of bone marrow disorders characterized by impaired blood cell production, which can prevent healthy blood cells from maturing properly. This may lead to complications such as anemia, increased susceptibility to infections, and bleeding. Chromosomal abnormalities and genetic changes may contribute to the development of MDS. These changes are important for disease classification, risk assessment, and evaluating the risk of progression to acute myeloid leukemia (AML).

MDS treatment is planned according to the disease risk category, genetic characteristics, the patient’s age, and overall health. Treatment options may include supportive care, blood transfusions, growth factors, hypomethylating agents, and allogeneic stem cell transplantation in eligible patients. Genetic and chromosomal analyses help characterize the disease and support clinical decision-making in treatment planning.

Genetic AlterationsMethodSample Type
Monosomy 5 ve 5q deletionFISHBone Marrow / Heparinized Blood
Monosomy 7 ve 7q deletionFISHBone Marrow / Heparinized Blood
Trisomy 8FISHBone Marrow / Heparinized Blood
Monosomy 20 ve 20q deletionFISHBone Marrow / Heparinized Blood
MLL (11q23.1-q23.3) rearrangementFISHBone Marrow / Heparinized Blood
Monosomy 17 ve TP53 deletion (17p13.1)FISHBone Marrow / Heparinized Blood
t(3;3)FISHBone Marrow / Heparinized Blood
MLLT3/MLL t(9;11)FISHBone Marrow / Heparinized Blood
MLL/MLLT1 t(11;19)FISHBone Marrow / Heparinized Blood

 

//
Our customer support team is here to answer your questions!